

Contraception in Women with Medical Complexities

Lori Gawron, MD, MPH
Assistant Professor
Department of OBGYN
University of Utah School of Medicine



Objectives


- Review US reproductive health epidemiology
- Discuss contraceptive resources and decisionmaking
 - Safety
 - Effectiveness
 - Availability (including accessibility and affordability)
 - Acceptability
- Case example



Healthy = Planned










Modern Contraception Works


The two-thirds of U.S. women at risk of unintended pregnancy who practice contraception consistently and correctly account for only 5% of unintended pregnancies.

Women at Risk (43 Million in 2008)



By consistency of method use all year

Unintended Pregnancies (3.1 Million)



By consistency of method use during month of conception



Chronic Diseases

- Prevalence of chronic medical conditions among reproductive age women is increasing
- Increased risk of unintended pregnancy in women with chronic diseases




Chronic Conditions

- Breast cancer
- Complicated valvular heart disease
- Cystic fibrosis
- Complicated diabetes
- Endometrial or ovarian cancer
- Epilepsy
- HTN
- Bariatric surgery
- HIV/AIDS
- Ischemic heart disease
- GTD
- Malignant liver tumors
- Peripartum cardiomyopathy
- Schistosomiasis

- Cirrhosis
- Sickle Cell
- Solid organ Tx
- Stroke
- Lupus
- Thrombogenic mutations
- TB
- Depression
- Obesity
- Rheumatoid arthritis
- IBD
- Asthma
- Thyroid Dx




Contraceptive Selection





One Key Question®



Oregon Foundation for Reproductive Health



Safety



Morbidity and Mortality Weekly Report (MMWR)


CDC > MMWR

U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Recommendations and Reports / July 29, 2016 / 65(3);1–104



Evidence-based guidance on the contraceptive safety for U.S. women with specific characteristics and medical conditions



Modified by the CDC from the WHO MEC

Six new medical diagnoses added- IBD, bariatric surgery, solid organ transplant, etc.



Why the MEC??

Can a teen use an IUD?

Can a woman on seizure meds use the patch?

Can a breastfeeding woman use the shot?



Can a diabetic / use the pill?





US MEC Categories

US Medical Eligibility Criteria (US MEC)



- Category 1: No restriction for the use of the contraceptive method
- Category 2: Advantages generally outweigh the theoretical or proven risks
- Category 3: Theoretical or proven risks usually outweigh the advantages
- Category 4: Unacceptable health risk if the contraceptive method is used



U.S. MEC

Condition	Sub-Condition	Cu-IUD	LNG-IUD	Implant	DMPA	POP	CHC	
		I C	I C	I C	I C	I C	I C	
Diabetes	a) History of gestational disease		1	1 1		1	1	
	b) Nonvascular disease							
	i) Non-insulin dependent	1	2	2 2		2	2	
	ii) Insulin dependent	1	2	2	2	2	2	
	c) Nephropathy/retinopathy/neuropathy [‡]	1	2	2	3	2	3/4*	
	 d) Other vascular disease or diabetes of >20 years' duration[‡] 	1	2	2	2 3		3/4*	
Dysmenorrhea	Severe	2	1	1	1	1	1	
Endometrial cancer [‡]		4 2	4 2	1	1	1	1	

US Medical Eligibility Criteria for Contraceptive Use. CDC 2016



U.S. SPR

Morbidity and Mortality Weekly Report (MMWR)

CDC > MMWR

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Recommendations and Reports / July 29, 2016 / 65(4);1-66

- Improve same day provision
- Avoid unnecessary screening or testing
- Limit barriers
- Provide evidence-based recommendations



Starting contraception

	Contraceptive method	is reasonably certain that the woman is not pregnant)	Additional contraception (i.e., back up) needed	Examinations or tests needed before initiation ¹
Co	pper-containing IUD	Anytime	Not needed	Bimanual examination and cervical inspection ²
Lev IUE	vonorgestrel-releasing O	Anytime	If >7 days after menses started, use back-up method or abstain for 7 days.	Bimanual examination and cervical inspection ²
lm	plant	Anytime	If >5 days after menses started, use back-up method or abstain for 7 days.	None
lnje	ectable	Anytime	If >7 days after menses started, use back-up method or abstain for 7 days.	None
	mbined hormonal ntraceptive	Anytime	If >5 days after menses started, use back-up method	Blood pressure measurement

CDC Selective Practice Recommendations. Available at: http://www.cdc.gov/reproductivehealth/UnintendedPregnancy/PDF/248124_Box1_App _B_D_Final_TAG508.pdf




Effectiveness

HOW WELL DOES BIRTH CONTROL WORK?

What is your chance of getting pregnant?














FYI, without birth control, over 90 in 100 young women get pregnant in a year.







This work by the UCSF School of Medicine Bixby Center and Bedsider is licensed as a Creative Commons Attribution - NonCommercial - NoDeriv 3.0 Unported License.



Availability Acceptability



Case #1

26yo G1P0 @ 28 weeks

SLE

+antiphospholipid antibodies

Chronic anticoagulation for h/o PE

Plans to breastfeed



Decision-making

Condition	Sub-Condition	Cu-IUD	LNG-IUD	Implant	DMPA	POP	CHC	
		I C	I C	I C	I C	I C	I C	
Systemic lupus erythematosus [†]	a) Positive (or unknown) antiphospholipid antibodies	1* 1*	3*	3*	3* 3*	3*	4*	
Deep venous thrombosis (DVT)/Pulmonary embolism (PE)	c) DVT/PE and established anticoagulant therapy for at least 3 months i) Higher risk for recurrent DVT/PE	2	2	2	2	2	4"	
Breastfeeding	a) <21 days postpartum b) 21 to <30 days postpartum i) With other risk factors for VTE		2* 2* 2* 2*		2* 2*	4* 3*		

Clarification: Persons with SLE are at increased risk for ischemic heart disease, stroke, and VTE. Categories assigned to such conditions in U.S. MEC should be the same for women with SLE who have these conditions. For all subconditions of SLE, classifications are based on the assumption that no other risk factors for cardiovascular disease are present; these classifications must be modified in the presence of such risk factors. Many women with SLE can be considered good candidates for most contraceptive methods, including hormonal contraceptives (73,77–94).

Evidence: Antiphospholipid antibodies are associated with a higher risk for both arterial and venous thrombosis (95,96).



Condition

Systemic lupus erythematosus¹

Deep venous throm (DVT)/Pulmonary embolism (PE)

Breastfeeding

Clarification: Breastfeeding provides important health benefits for mother and infant. The U.S. Department of Health and Human Services recommends increasing the proportion of infants initially breastfed, exclusively breastfed through 6 months of life, and continuing breastfeeding through at least 1 year of life as key public health goals (49).

Evidence: Two small, randomized controlled trials found no adverse impact on breastfeeding with initiation of etonogestrel implants within 48 hours postpartum. Other studies found that initiation of POPs, injectables, and implants at ≤6 weeks postpartum compared with nonhormonal use had no detrimental effect on breastfeeding outcomes or infant health, growth, and development in the first year postpartum. In general, these studies are of poor quality, lack standard definitions of breastfeeding or outcome measures, and have not included premature or ill infants (50,51).

Comment: Certain women might be at risk for breastfeeding difficulties, such as women with previous breastfeeding difficulties, certain medical conditions, and certain perinatal complications and those who deliver preterm. For these women, as for all women, discussions about contraception for breastfeeding women should include information about risks, benefits, and alternatives.





Decision-making

Condition	Sub-Condition	Cu-	Cu-IUD		LNG-IUD		Implant		DMPA		POP		HC
		1	C	1	C	1	C	1	C	1	C		C
Systemic lupus erythematosus [†]	a) Positive (or unknown) antiphospholipid antibodies	1* 1*		3*		3*		3* 3*		3*		* 4*	
Deep venous thrombosis (DVT)/Pulmonary	onary therapy for at least 3 months												
embolism (PE)	i) Higher risk for recurrent DVT/PE	2		2	2	2		2		2		4*	
Breastfeeding	a) <21 days postpartum					2*		2*		2*		4*	
	b) 21 to <30 days postpartum												
	i) With other risk factors for VTE					2	*	2*		2*		3*	+
Postpartum	a) <10 minutes after delivery of the placenta												
(in breastfeeding or non- breastfeeding women, including cesarean delivery)	i) Breastfeeding	1	*	2	*								
	ii) Nonbreastfeeding	1	*	1	*								
	b) 10 minutes after delivery of the placenta to <4 weeks	2	*	2	*								
	c) ≥4 weeks	1	*	1	*								

d) Postpartum sepsis



Decision-making

- Safety
- -Effectiveness
- Availability (including accessibility and affordability)
 - Insurance
 - Provider training
- Acceptability
 - Side effects- may be positive or negative
 - Non-contraceptive benefits
 - Birth spacing/ pregnancy planning
 - Partner



Summary

- Reproductive planning is critical for women with chronic diseases
- –CDC MEC and SPR assist in safety
- Contraceptive decision-making is complex- especially in chronic diseases
 - Safety
 - Effectiveness
 - Availability (including accessibility and affordability)
 - Acceptability



Questions?